An Introduction to Dermatological Diseases
Autoimmunity and deregulation of the immune system contribute to many skin diseases including systemic sclerosis, dermatomyositis, psoriasis, vitiligo, alopecia areata and lichen sclerosus; as well as inflammatory diseases such as hidradenitis suppurativa, allergic contact dermatitis and atopic eczema; and also autoimmune blistering diseases, including pemphigus vulgaris, bullous pemphigoid, epidermolysis bullosa acquisita and dermatitis herpetiformis. Established treatments include systemic corticosteroids and immunosuppressive therapies, while new therapies in development include biologic therapies targeting cytokines such as tumour necrosis factor alpha (TNF-alpha) and interleukins IL-23 and IL-17; enzymes such as Janus kinase-1 (JAK-1); and the regulatory proteinretinoic acid receptor-related-orphan-receptor-gamma t (RORγt).
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Dermatological Diseases Content
Victoria P. Werth, ACR 2022: The phase 3 DeterMine trial of lenabasum in dermatomyositis
DeterMine (NCT03813160) was a phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of lenabasum for the treatment of dermatomyositis. It was a pleasure to talk with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) to discuss the aims, design, eligibility criteria and findings of the phase 3 study. This information […]
Prurigo nodularis: Improving awareness, diagnosis, management and quality of life
Watch three experts discuss the symptom burden faced by patients with prurigo nodularis, and how clinicians can optimize diagnosis and treatment of the disease.
- Define the burden of disease and unmet need for prurigo nodularis
- Identify the differential diagnoses for patients with prurigo nodularis and recall the range of treatment and management options available
- Evaluate the emerging treatment options for the management of prurigo nodularis and how these may impact current clinical practice
Loretta Fiorillo, EADV 2022: Findings from the Phase 3 Study of Apremilast in Paediatric Plaque Psoriasis
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. touchIMMUNOLOGY were delighted to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) to discuss the the aims, design and eligibility criteria of the study investigating apremilast in paediatric patients with moderate to severe plaque psoriasis and how […]
Loretta Fiorillo, EADV 2022: Apremilast Treatment for Plaque Psoriasis in Paediatric Patients
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. It was a pleasure to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) around the unmet needs in the treatment of plaque psoriasis in paediatric patients and the clinical evidence supporting apremilast in this indication. The abstract […]
Gil Yosipovitch, EADV 2022: LIBERTY-PN-PRIME Study – Dupilumab for the Treatment of Prurigo Nodularis
LIBERTY-PN PRIME (NCT04183335) was a randomised, double-blind, placebo-controlled phase 3 trial, investigating dupilumab for the treatment of prurigo nodularis. touchIMMUNOLOGY caught up with Prof. Gil Yosipovitch (Miller School of Medicine, University of Miami, Miami, FL, USA) to discuss the aims, design and eligibility criteria of the phase 3 study and the findings in terms of itch […]
Understanding alopecia areata: Current perspectives and emerging therapies for a complex disease
Watch two expert dermatologists discuss AA, focusing on issues related to disease severity, pathophysiology and treatment with JAK inhibitors.
- Recognize the risk factors, symptoms, and burden of alopecia areata
- Describe the pathophysiology and immunological mechanisms involved in alopecia areata
- Evaluate how emerging therapies for alopecia areata may be incorporated into the current landscape and change clinical practice
Jonathan A Bernstein, EAACI 2022: Findings from the Phase 2b Extension Study of Ligelizumab in Chronic Spontaneous Urticaria
Ligelizumab is a monoclonal anti-immunoglobulin (Ig) E antibody that has been investigated in the treatment of chronic spontaneous urticaria. touchIMMUNOLOGY were delighted to speak with Prof. Jonathan A Bernstein (University of Cincinnati; Bernstein Allergy Group & Bernstein Clinical Research Center, Cincinnati, OH, USA) around the aims, design and findings from the phase 2b extension study […]
Ana Maria Giménez-Arnau, EAACI 2022: A Phase 2b Study of Remibrutinib for Chronic Spontaneous Urticaria
Remibrutinib is an oral BTK inhibitor currently being investigated in a phase 2 trial in urticaria. It was a pleasure to talk with Prof. Ana Maria Giménez-Arnau (Hospital del Mar. IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain) around the safety findings from the long term extension of a phase 2b study of remibrutinib in chronic […]
Ana Maria Giménez-Arnau, EAACI 2022: Pathology and Unmet Needs in Chronic Spontaneous Urticaria
It was a pleasure to talk with Prof. Ana Maria Giménez-Arnau (Hospital del Mar. IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain) to discuss the unmet needs in the treatment of chronic spontaneous urticaria and the rationale for investigating remibrutinib in this indication. The abstract ‘Long-term safety and tolerability of remibrutinib (LOU064) in Phase 2b study […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!